We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 1b/2a trial evaluates safety and efficacy of Bexicaserin in participants with epileptic encephalopathies, suggesting potential benefits.
No takes yet. Share an insight, caveat, or question.
Le et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: